Neurogenesis After Traumatic Brain Injury

R. Mark Richardson, Dong Sun, Ross Bullock

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

The relatively preliminary studies described here have begun to delineate aspects of the neurogenic response to TBI that should determine whether this phenomenon can be manipulated for therapeutic purposes. Clarifying the time course over which NPC proliferation, migration, differentiation, and integration occur after injury is necessary for defining therapeutic windows in which to attempt to augment these processes. From studies thus far, it is known that there are an increased number of neurons added to the rodent hippocampal circuitry, which survive for at least several weeks after injury. Without longer outcome data, it is still not certain that this event is not transitory, and, of course, its verification in the human brain is still pending. Likewise, it seems that neuroblasts from the rodent SVZ migrate toward damaged cortical areas; however, the verification of this phenomenon in the human brain would be even more remarkable, because, thus far, there is no evidence for baseline long-distance SVZ NPC migration in the human brain (along the lines of the rodent rostral migratory stream). It is likely that human NPCs do proliferate in response to TBI, but measuring this occurrence must be the first step in assessing the applicability of findings in rodent studies to the potential development of neurogenic therapies to be tested in clinical trials. Additionally, it remains challenging to attribute any improvement in neurologic function to the augmentation of neurogenesis by therapeutic agents, because many neurogenic compounds have complex effects on central nervous system physiology. Nonetheless, neurogenesis remains an exciting prospect for exploration in TBI research.

Original languageEnglish
Pages (from-to)169-181
Number of pages13
JournalNeurosurgery Clinics of North America
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Neurogenesis
Rodentia
Brain
Nervous System Physiological Phenomena
Wounds and Injuries
Therapeutics
Nervous System
Central Nervous System
Clinical Trials
Neurons
Traumatic Brain Injury
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Neurogenesis After Traumatic Brain Injury. / Richardson, R. Mark; Sun, Dong; Bullock, Ross.

In: Neurosurgery Clinics of North America, Vol. 18, No. 1, 01.01.2007, p. 169-181.

Research output: Contribution to journalArticle

Richardson, R. Mark ; Sun, Dong ; Bullock, Ross. / Neurogenesis After Traumatic Brain Injury. In: Neurosurgery Clinics of North America. 2007 ; Vol. 18, No. 1. pp. 169-181.
@article{dba8506e893945019373557b93d37a76,
title = "Neurogenesis After Traumatic Brain Injury",
abstract = "The relatively preliminary studies described here have begun to delineate aspects of the neurogenic response to TBI that should determine whether this phenomenon can be manipulated for therapeutic purposes. Clarifying the time course over which NPC proliferation, migration, differentiation, and integration occur after injury is necessary for defining therapeutic windows in which to attempt to augment these processes. From studies thus far, it is known that there are an increased number of neurons added to the rodent hippocampal circuitry, which survive for at least several weeks after injury. Without longer outcome data, it is still not certain that this event is not transitory, and, of course, its verification in the human brain is still pending. Likewise, it seems that neuroblasts from the rodent SVZ migrate toward damaged cortical areas; however, the verification of this phenomenon in the human brain would be even more remarkable, because, thus far, there is no evidence for baseline long-distance SVZ NPC migration in the human brain (along the lines of the rodent rostral migratory stream). It is likely that human NPCs do proliferate in response to TBI, but measuring this occurrence must be the first step in assessing the applicability of findings in rodent studies to the potential development of neurogenic therapies to be tested in clinical trials. Additionally, it remains challenging to attribute any improvement in neurologic function to the augmentation of neurogenesis by therapeutic agents, because many neurogenic compounds have complex effects on central nervous system physiology. Nonetheless, neurogenesis remains an exciting prospect for exploration in TBI research.",
author = "Richardson, {R. Mark} and Dong Sun and Ross Bullock",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.nec.2006.10.007",
language = "English",
volume = "18",
pages = "169--181",
journal = "Neurosurgery Clinics of North America",
issn = "1042-3680",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Neurogenesis After Traumatic Brain Injury

AU - Richardson, R. Mark

AU - Sun, Dong

AU - Bullock, Ross

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The relatively preliminary studies described here have begun to delineate aspects of the neurogenic response to TBI that should determine whether this phenomenon can be manipulated for therapeutic purposes. Clarifying the time course over which NPC proliferation, migration, differentiation, and integration occur after injury is necessary for defining therapeutic windows in which to attempt to augment these processes. From studies thus far, it is known that there are an increased number of neurons added to the rodent hippocampal circuitry, which survive for at least several weeks after injury. Without longer outcome data, it is still not certain that this event is not transitory, and, of course, its verification in the human brain is still pending. Likewise, it seems that neuroblasts from the rodent SVZ migrate toward damaged cortical areas; however, the verification of this phenomenon in the human brain would be even more remarkable, because, thus far, there is no evidence for baseline long-distance SVZ NPC migration in the human brain (along the lines of the rodent rostral migratory stream). It is likely that human NPCs do proliferate in response to TBI, but measuring this occurrence must be the first step in assessing the applicability of findings in rodent studies to the potential development of neurogenic therapies to be tested in clinical trials. Additionally, it remains challenging to attribute any improvement in neurologic function to the augmentation of neurogenesis by therapeutic agents, because many neurogenic compounds have complex effects on central nervous system physiology. Nonetheless, neurogenesis remains an exciting prospect for exploration in TBI research.

AB - The relatively preliminary studies described here have begun to delineate aspects of the neurogenic response to TBI that should determine whether this phenomenon can be manipulated for therapeutic purposes. Clarifying the time course over which NPC proliferation, migration, differentiation, and integration occur after injury is necessary for defining therapeutic windows in which to attempt to augment these processes. From studies thus far, it is known that there are an increased number of neurons added to the rodent hippocampal circuitry, which survive for at least several weeks after injury. Without longer outcome data, it is still not certain that this event is not transitory, and, of course, its verification in the human brain is still pending. Likewise, it seems that neuroblasts from the rodent SVZ migrate toward damaged cortical areas; however, the verification of this phenomenon in the human brain would be even more remarkable, because, thus far, there is no evidence for baseline long-distance SVZ NPC migration in the human brain (along the lines of the rodent rostral migratory stream). It is likely that human NPCs do proliferate in response to TBI, but measuring this occurrence must be the first step in assessing the applicability of findings in rodent studies to the potential development of neurogenic therapies to be tested in clinical trials. Additionally, it remains challenging to attribute any improvement in neurologic function to the augmentation of neurogenesis by therapeutic agents, because many neurogenic compounds have complex effects on central nervous system physiology. Nonetheless, neurogenesis remains an exciting prospect for exploration in TBI research.

UR - http://www.scopus.com/inward/record.url?scp=33846471559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846471559&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2006.10.007

DO - 10.1016/j.nec.2006.10.007

M3 - Article

VL - 18

SP - 169

EP - 181

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

SN - 1042-3680

IS - 1

ER -